KROS
Keros Therapeutics Inc (KROS)
Healthcare • NASDAQ • $12.07+3.69%
- Symbol
- KROS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $12.07
- Daily Change
- +3.69%
- Market Cap
- $238.84M
- Trailing P/E
- 5.25
- Forward P/E
- -2.38
- 52W High
- $22.55
- 52W Low
- $10.42
- Analyst Target
- $21.83
- Dividend Yield
- N/A
- Beta
- 0.95
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop,…
Company websiteResearch KROS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.